4.7 Article

Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis

Journal

NEUROLOGY
Volume 92, Issue 13, Pages E1507-E1516

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0000000000007178

Keywords

-

Funding

  1. Ministry of Economy and Competitiveness of Spain [FIS PI15/0070]
  2. Fundacion Genzyme
  3. ECTRIMS

Ask authors/readers for more resources

Objective To investigate the effect of menarche, pregnancies, and breastfeeding on the risk of developing multiple sclerosis (MS) and disability accrual using a multivariate approach based on a large prospective cohort of patients with clinically isolated syndrome (CIS). Methods A cross-sectional survey of the reproductive information of female participants in a CIS cohort was performed. We examined the relationship of age at menarche with the risk of clinically definite MS (CDMS), McDonald 2010 MS, and Expanded Disability Status Scale (EDSS) 3.0 and 6.0. The effect of pregnancy (before and after CIS) and breastfeeding in the risk of CDMS, McDonald 2010 MS, and EDSS 3.0 was also examined. Univariate and multivariate analyses were performed and findings were confirmed using sensitivity analyses and a propensity score model. Results The data of 501 female participants were collected. Age at menarche did not correlate with age at CIS and was not associated with the risk of CDMS or EDSS 3.0 or 6.0. Pregnancy before CIS was protective for CDMS in the univariate analysis, but the effect was lost in the multivariate model and did not modify the risk of EDSS 3.0. Pregnancy after CIS was protective for both outcomes in univariate and multivariate analyses when pregnancy was considered a baseline variable, but the protective effect disappeared when analyzed as a time-dependent event. Breastfeeding did not modify the risk for the 3 outcomes. Conclusions These results demonstrate that menarche, pregnancies, and breastfeeding did not substantially modify the risk of CDMS or disability accrual using a multivariable and time-dependent approach.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Clinical Neurology

Myelin Oligodendrocyte Glycoprotein Antibodies in Adults with a First Demyelinating Event Suggestive of Multiple Sclerosis

Javier Villacieros-Alvarez, Carmen Espejo, Georgina Arrambide, Mireia Castillo, Pere Carbonell-Mirabent, Marta Rodriguez, Luca Bollo, Joaquin Castillo, Manuel Comabella, Ingrid Galan, Luciana Midaglia, Neus Mongay-Ochoa, Carlos Nos, Jordi Rio, Breogan Rodriguez-Acevedo, Jaume Sastre-Garriga, Carmen Tur, Angela Vidal-Jordana, Andreu Vilaseca, Ana Zabalza, Cristina Auger, Alex Rovira, Xavier Montalban, Mar Tintore, Alvaro Cobo-Calvo

Summary: MOG-Ab are rare in adults with a first demyelinating event suggestive of MS. However, it is suggested to determine these antibodies in patients with ON and absence of CSF-OBs based on the results.

ANNALS OF NEUROLOGY (2023)

Article Clinical Neurology

A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients

Rene Carvajal, Carmen Tur, Xavier Martinez-Gomez, Luca Bollo, Juliana Esperalba, Marta Rodriguez, Agustin Pappolla, Alvaro Cobo-Calvo, Pere Carbonell, Blanca Borras-Bemejo, Jordi Rio, Joaquin Castillo, Nathane Braga, Neus Mongay-Ochoa, Jose Angel Rodrigo-Pendas, Angela Vidal-Jordana, Georgina Arrambide, Breogan Rodriguez-Acevedo, Ana Zabalza, Luciana Midaglia, Ingrid Galan, Manuel Comabella, Jaume Sastre-Garriga, Xavier Montalban, Mar Tintore, Susana Otero-Romero

Summary: A single-dose attempt of VAR and/or MMR vaccines could effectively protect almost two-thirds of patients with multiple sclerosis and reduce delays in immunosuppressive treatment initiation.

MULTIPLE SCLEROSIS JOURNAL (2023)

Article Clinical Neurology

Do the current MS clinical course descriptors need to change and if so how? A survey of the MS community

Alan J. Thompson, Marcello Moccia, Maria Pia Amato, Peter A. Calabresi, Marcia Finlayson, Annie Hawton, Fred D. Lublin, Ruth Ann Marrie, Xavier Montalban, Michael Panzara, Maria Pia Sormani, Jon Strum, Barbara G. Vickrey, Timothy Coetzee

Summary: The survey results show that stakeholders of multiple sclerosis (MS) believe that the current clinical course descriptors need to change and support a mechanism-driven framework for describing MS. Clinical validation and ease of communication with patients are the most important considerations when developing a new framework.

MULTIPLE SCLEROSIS JOURNAL (2023)

Article Clinical Neurology

Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton's tyrosine kinase inhibitor

Amit Bar-Or, Anne H. Cross, Anthony L. Cunningham, Yann Hyvert, Andrea Seitzinger, Hans Guehring, Elise E. Drouin, Nektaria Alexandri, Davorka Tomic, Xavier Montalban

Summary: A post hoc analysis showed that Evobrutinib, an investigational drug for patients with relapsing multiple sclerosis (RMS), has an impact on immune responses. The results suggest that the drug acts as an immunomodulator, inhibiting aberrant immune cell responses while maintaining responsiveness to foreign and recall antigens.

MULTIPLE SCLEROSIS JOURNAL (2023)

Article Immunology

Teriflunomide and Epstein-Barr virus in a Spanish multiple sclerosis cohort: in vivo antiviral activity and clinical response

Maria Inmaculada Dominguez-Mozo, Ines Gonzalez-Suarez, Luisa Maria Villar, Lucienne Costa-Frossard, Noelia Villarrubia, Yolanda Aladro, Belen Pilo, Xavier Montalban, Manuel Comabella, Ignacio Casanova-Peno, Maria Luisa Martinez-Gines, Jose Manuel Garcia-Dominguez, Maria Angel Garcia-Martinez, Rafael Arroyo, Roberto Alvarez-Lafuente

Summary: Treatment with teriflunomide reduced IgG antibody titers against EBV and HHV-6. Higher levels of EBNA-1 IgG prior to teriflunomide initiation were associated with a better clinical response.

FRONTIERS IN IMMUNOLOGY (2023)

Article Immunology

Molecular signature associated with cladribine treatment in patients with multiple sclerosis

Nicolas Fissolo, Laura Calvo-Barreiro, Herena Eixarch, Ursula Boschert, Luisa M. Villar, Lucienne Costa-Frossard, Mireia Ferrer, Alex Sanchez, Eva Borras, Eduard Sabido, Carmen Espejo, Xavier Montalban, Manuel Comabella

Summary: This study characterized the transcriptomic and proteomic profiles induced by cladribine in blood cells, and identified potential treatment response biomarkers to cladribine in patients with multiple sclerosis.

FRONTIERS IN IMMUNOLOGY (2023)

Review Cell Biology

Liquid Biopsy in Neurological Diseases

Sunny Malhotra, Mari Carmen Martin Miras, Agustin Pappolla, Xavier Montalban, Manuel Comabella

Summary: Liquid biopsy is a non-invasive method for studying early-stage biomarkers. It involves extracting and analyzing non-solid biological tissues without invasive procedures to determine disease prognosis. Liquid biopsy components, such as extracellular vesicles, microRNAs, and circulating tumor cells, have shown potential as valuable biomarkers in various neurological conditions. This review provides an overview of liquid biopsy and discusses its applications, future directions, and potential limitations.

CELLS (2023)

Meeting Abstract Clinical Neurology

Longer-term safety and efficacy of ofatumumab in recently diagnosed and treatment naive patients is consistent with the overall population in the ALITHIOS open-label extension study

Rozhin Ashgari, Jutta Gaertner, Stephen Hauser, Amit Bar-Or, Xavier Montalban, Jeffrey Cohen, Derrick Robertson, Anne Cross, Carrie Hersh, Kumaran Deiva, Karlsson Goeri, Ayan Das Gupta, Ronald Zielman, Soudeh Ansari, Bernd Kieseier, Ludwig Kappos

MULTIPLE SCLEROSIS JOURNAL (2023)

Meeting Abstract Clinical Neurology

An Update on the Clinical use of Dimethyl Fumarate, Including as a Recently Licensed Therapy in China, Using a Modified Delphi Method: Interim Results

Michael Barnett, Andrew Chan, Huiyu Feng, Kazuo Fujihara, Gavin Giovannoni, Ralf Gold, Xavier Montalban, Fu-Dong Shi, Maria Tintore, Qun Xue, Chunsheng Yang, Hongyu Zhou

MULTIPLE SCLEROSIS JOURNAL (2023)

Review Clinical Neurology

Clinical use of dimethyl fumarate in multiple sclerosis treatment: an update to include China, using a modified Delphi method

Ralf Gold, Michael Barnett, Andrew Chan, Huiyu Feng, Kazuo Fujihara, Gavin Giovannoni, Xavier Montalban, Fu-Dong Shi, Mar Tintore, Qun Xue, Chunsheng Yang, Hongyu Zhou

Summary: Dimethyl fumarate (DMF) is a widely used oral disease-modifying therapy for multiple sclerosis (MS) with proven efficacy and safety. Existing data on DMF are primarily derived from populations outside of Asia. However, recent approval for use in China suggests its relevance to the Chinese population as well.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2023)

Meeting Abstract Clinical Neurology

Effect of RIPK1 Inhibitor, SAR443820, on Serum Neurofilament Light Levels in Patients with Multiple Sclerosis: A Phase 2 Trial Design

Xavier Montalban, Jens Kuhle, Robert Fox, Timothy Vartanian, Dana Horakova, Massimo Filippi, Ernest Roos, Erik Wallstroem, Nazem Atassi

NEUROLOGY (2023)

Meeting Abstract Clinical Neurology

Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib for Relapsing Multiple Sclerosis Over 3.5 Years of Treatment: An Ongoing Phase II Open-Label Extension

Xavier Montalban, Jerry S. Wolinsky, Douglas L. Arnold, Martin S. Weber, Karolina Piasecka-Stryczynska, Davorka Tomic, Andrea Seitzinger, Hans Guehring

NEUROLOGY (2023)

Meeting Abstract Clinical Neurology

Predicting MRI Changes in Patients with MS in the Absence of Acute Inflammation

Carmen Tur, Zhaonan Sun, Daniel Bradley, Cynthia Grossman, Xavier Montalban, Alex Rovira, Mar Tintore, Nolan Campbell, Elizabeth Fisher

NEUROLOGY (2023)

Meeting Abstract Clinical Neurology

Effect of RIPK1 Inhibitor, SAR443820, on Serum Neurofilament Light Chain Levels in Patients with Multiple Sclerosis: A Phase 2 Trial Design

X. Montalban, J. Kuhle, R. Fox, T. Vartanian, D. Horakova, M. Filippi, E. Roos, V. Nicolas, E. Wallstroem, N. Atassi

MULTIPLE SCLEROSIS JOURNAL (2023)

Meeting Abstract Clinical Neurology

Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib for Relapsing Multiple Sclerosis Over 3.5 Years of Treatment: An Ongoing Phase II Open-Label Extension

X. Montalban, J. S. Wolinsky, D. L. Arnold, M. S. Weber, K. Piasecka-Stryczynska, D. Tomic, A. Seitzinger, H. Guehring

MULTIPLE SCLEROSIS JOURNAL (2023)

No Data Available